Janney Montgomery Scott LLC Buys New Holdings in Repligen Co. (RGEN)
Janney Montgomery Scott LLC bought a new stake in Repligen Co. (NASDAQ:RGEN) in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 14,053 shares of the biotechnology company’s stock, valued at approximately $539,000.
Several other large investors have also made changes to their positions in RGEN. Quantbot Technologies LP purchased a new stake in shares of Repligen in the second quarter valued at about $120,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Repligen in the second quarter valued at about $123,000. Victory Capital Management Inc. raised its holdings in shares of Repligen by 17.7% in the second quarter. Victory Capital Management Inc. now owns 4,001 shares of the biotechnology company’s stock valued at $166,000 after buying an additional 601 shares during the last quarter. SG Americas Securities LLC purchased a new stake in shares of Repligen in the third quarter valued at about $180,000. Finally, Pinebridge Investments L.P. increased its stake in shares of Repligen by 1.7% during the second quarter. Pinebridge Investments L.P. now owns 4,491 shares of the biotechnology company’s stock worth $186,000 after acquiring an additional 76 shares during the period. 82.50% of the stock is owned by institutional investors and hedge funds.
Repligen Co. (RGEN) opened at $35.72 on Tuesday. Repligen Co. has a one year low of $28.48 and a one year high of $46.81. The stock has a market cap of $1,560.00, a PE ratio of 60.54, a PEG ratio of 2.31 and a beta of 1.04.
Repligen (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, November 9th. The biotechnology company reported $0.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. Repligen had a net margin of 16.93% and a return on equity of 7.57%. The business had revenue of $36.58 million for the quarter, compared to analyst estimates of $35.69 million. During the same period in the previous year, the business posted $0.08 earnings per share. The business’s revenue was up 48.2% compared to the same quarter last year. research analysts expect that Repligen Co. will post 0.61 EPS for the current fiscal year.
In other Repligen news, VP Howard Benjamin sold 12,729 shares of the company’s stock in a transaction dated Thursday, December 14th. The shares were sold at an average price of $35.34, for a total transaction of $449,842.86. Following the transaction, the vice president now directly owns 36,554 shares in the company, valued at $1,291,818.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.50% of the company’s stock.
RGEN has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. initiated coverage on shares of Repligen in a research note on Tuesday, December 5th. They set an “overweight” rating and a $42.00 price target on the stock. Stephens reiterated an “overweight” rating and set a $50.00 price target on shares of Repligen in a research note on Tuesday, September 26th. Zacks Investment Research lowered shares of Repligen from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. TheStreet lowered shares of Repligen from a “b-” rating to a “c” rating in a research note on Monday, November 13th. Finally, CL King initiated coverage on shares of Repligen in a research note on Monday, November 13th. They set a “buy” rating and a $41.00 price target on the stock. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $44.38.
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).
Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with Analyst Ratings Network's FREE daily email newsletter.